• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[使用选择性单胺氧化酶-A抑制剂吗氯贝胺和马普替林治疗的心理测量结果]

[Psychometric findings in treatment using the selective MAO-A inhibitors moclobemide and maprotiline].

作者信息

Classen W

机构信息

Psychiatrische Universitätsklinik, Würzburg.

出版信息

Psychiatr Prax. 1989 Aug;16 Suppl 1:41-3.

PMID:2587675
Abstract

Two groups of depressed patients were treated either with a selective MAO-A-inhibitor, moclobemide (n = 13), or a tetracyclic antidepressant, maprotiline (n = 18), in a 28 days lasting investigation. Before and after treatment psychopathologic symptoms were rated using Hamilton Depression Scale, motor performance were proven by the Motorische Leistungs-Serie (MLS), and acoustic and visual sensorimotor performance were investigated using Bettendorff Reaktiometer T96. Deterioration of psychomotor performance were seen in patients without amelioration of their psychopathologic symptoms, especially when treated with moclobemide. These findings were regarded as a hint that possibly the therapeutic agent interacts with the wrong transmitter system and perhaps this is the reason for the deterioration of psychomotor functions.

摘要

在一项为期28天的研究中,两组抑郁症患者分别接受选择性单胺氧化酶A抑制剂吗氯贝胺(n = 13)或四环类抗抑郁药马普替林(n = 18)治疗。治疗前后使用汉密尔顿抑郁量表对精神病理症状进行评分,通过运动能力系列测试(MLS)评估运动表现,并使用贝滕多夫T96反应计研究听觉和视觉感觉运动表现。在精神病理症状未改善的患者中观察到精神运动表现恶化,尤其是接受吗氯贝胺治疗的患者。这些发现被认为是一个提示,即治疗药物可能与错误的递质系统相互作用,这可能是精神运动功能恶化的原因。

相似文献

1
[Psychometric findings in treatment using the selective MAO-A inhibitors moclobemide and maprotiline].[使用选择性单胺氧化酶-A抑制剂吗氯贝胺和马普替林治疗的心理测量结果]
Psychiatr Prax. 1989 Aug;16 Suppl 1:41-3.
2
Psychometric alterations in treatment with the MAO-A-inhibitor moclobemide.单胺氧化酶A抑制剂吗氯贝胺治疗中的心理测量学改变。
J Neural Transm Suppl. 1990;32:185-8. doi: 10.1007/978-3-7091-9113-2_27.
3
[Treatment of depression using MAO-A inhibitors: an open study of a direct switch from moclobemide to tri-/tetracyclic antidepressants].使用单胺氧化酶-A抑制剂治疗抑郁症:从吗氯贝胺直接转换为三环/四环抗抑郁药的开放性研究
Psychiatr Prax. 1989 Aug;16 Suppl 1:44-7.
4
Moclobemide and maprotiline in the treatment of inpatients with major depressive disorder.吗氯贝胺与马普替林治疗重度抑郁症住院患者的疗效观察
J Neural Transm Suppl. 1989;28:45-52.
5
Multicenter double-blind study of moclobemide and maprotiline.吗氯贝胺与马普替林的多中心双盲研究。
Clin Neuropharmacol. 1994;17 Suppl 1:S38-49. doi: 10.1097/00002826-199417001-00006.
6
Combination therapy using moclobemide with tricyclic and tetracyclic antidepressants to treat therapy-resistant depression.使用吗氯贝胺与三环和四环抗抑郁药联合治疗难治性抑郁症。
Pharmacopsychiatry. 1997 May;30(3):93-6. doi: 10.1055/s-2007-979489.
7
[The Eppendorf Mood and Motivation Scale as assessment procedure in the clinical evaluation of an antidepressive agent].
Fortschr Med. 1982 Dec 2;100(45):2111-7.
8
[Moclobemide in the long-term treatment of depressed patients].[吗氯贝胺用于抑郁症患者的长期治疗]
Psychiatr Prax. 1989 Aug;16 Suppl 1:48-50.
9
Comparison of the efficacy and tolerability of moclobemide and maprotiline in depressed patients treated by general practitioners.全科医生治疗的抑郁症患者中吗氯贝胺与马普替林的疗效及耐受性比较。
Clin Neuropharmacol. 1994;17 Suppl 1:S29-37. doi: 10.1097/00002826-199417001-00005.
10
[Double-blind comparison of the effects of a new tricyclic antidepressant (Lofepramine) and a tetracyclic antidepressant (maprotiline)].
Int Pharmacopsychiatry. 1977;12(2):65-71.

引用本文的文献

1
Psychomotor performance and subjective symptoms at low level toluene exposure.低水平甲苯暴露下的精神运动表现和主观症状。
Occup Environ Med. 2002 Apr;59(4):263-8. doi: 10.1136/oem.59.4.263.